Local News: Waunakee, WI 

 | 

Sign Up

 | 

Sign In

Advertisment

Elan Corporation Plc

Elan Corporation Plc News Editors

RoboBlogger

I edit this news page on Topix when no humans are available to help.

People just like you make Elan Corporation Plc News on Topix better every day. If you're interested in becoming an editor, apply today!

Edits History | Editor Blog

RSS icon mobile icon

Elan Corporation Plc News

News on Elan Corporation Plc continually updated from thousands of sources around the net.

Yesterday | American Chronicle

News and FDA Updates for Cubist

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Comment?

Related Topix: Healthcare Law, Law, Biotech, Food and Drug Administration, Medicine, Cubist Pharmaceuticals, Healthcare Industry, Technical Services, Opinion

Tue Dec 15, 2009

Irish Examiner

Elan cuts high doses in drugs trial

ELAN has ceased the two highest doses in clinical trials of one of its main Alzheimera TMs treatments following the deaths of nine people, even though those deaths have not been directly linked to the trial.

Comment?

Related Topix: Biotech

The Motley Fool

Forget the Higher Doses

High doses of drugs, Alzheimer's, and Elan just don't go well together. Elan had to drop the highest dose of bapineuzumab earlier this year and now a second drug, ELND005, will need to do the same.

Comment?

Related Topix: Biotech, Transition Therapeutics, Medicine, Human Genome Sciences, Healthcare Industry, Johnson and Johnson, Pfizer

Mon Dec 14, 2009

PR-inside.com

Elan Drug Technologies Announces First Japanese Approval of Product...

Elan Drug Technologies, a business unit of Elan Corporation, plc announces the approval by the Japanese Ministry of Health, Labour and Welfare of EMEND A for the treatment of cancer chemotherapy-induced nausea and vomiting.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Merck , Food and Drug Administration

Fri Dec 11, 2009

The Motley Fool

Gilead Gets the Experts on Its Side

Gilead Sciences couldn't convince the Food and Drug Administration last year to approve its inhaled antibiotic treatment for cystic fibrosis-related infections, but now it's got a panel of experts on its side.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Food and Drug Administration, Azactam, Aztreonam (generic), Medication, Pfizer, Johnson and Johnson

Wed Dec 09, 2009

Freshnews

Elan to Present at Deutsche Bank Securities Biotech Boston Confab Conference

Elan Corporation, plc today announced that it will present at the Deutsche Bank Securities Biotech Boston Confab Conference, on Tuesday, December 15, 2009, at 10:30 a.m. Eastern Time and 3:30 p.m. GMT.

Comment?

Related Topix: Biotech, Science / Technology

Sun Dec 06, 2009

American Chronicle

News and FDA Updates for Biomagnetics

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Comment?

Related Topix: Healthcare Law, Law, Food and Drug Administration, HIV/AIDS, Health, Medicine, Malaria, Startups, Biotime, Biotech, Opinion

Fri Dec 04, 2009

The Motley Fool

Our Final Offer (Maybe)! That's a FACT

There are two rules in negotiations. Don't be the first to name a number and don't get in a bidding war with yourself.

Comment?

Related Topix: Biotech, Biogen Idec, First Albany Companies, Investment Banking, Financial Services, Investment Services, Trubion Pharmaceuticals, Johnson and Johnson, Medicine, Healthcare Industry

Wed Dec 02, 2009

The Motley Fool

Tired of Waiting, Teva Advances

Teva Pharmaceutical has decided it's not worth waiting for the U.S. government to establish a pathway for approval of generic versions of biologic drugs.

Comment?

Related Topix: Biotech, Teva Pharmaceutical Industries, Medicine, Amgen, Healthcare Industry, Healthcare Law, Law, Food and Drug Administration, Novartis

Thu Nov 12, 2009

Business Wire

Public relations, press release distribution, investor relations, SEC filing

DUBLIN, Ireland-- --Elan Corporation, plc today announced that it will present at the Lazard Capital Markets 6th Annual Healthcare Conference, on Tuesday, November 17, 2009 a... 11/11/2009 - 01:55 AM print24 lowers prices RADEBEUL, Germany-- --Klaus Sauer, Managing Director of print24, explained the company's strategy: "Our philosophy is to deliver ...

Comment?

Related Topix: Biotech, Ireland, World News, South Africa, Startups, Openwave Systems, Wireless, Emerging Technology, Tampa Metro

Tue Nov 10, 2009

TheStreet.com

'Mad Money Lightning Round': Buy Bucyrus on Weakness

Here's what Jim Cramer had to say about some of the stocks that callers offered up during the "Mad Money Lightning Round" Tuesday evening.

Comment?

Related Topix: Mad Money, Entertainment, Television, Financial Markets, Biotech, Medicine, Gilead Sciences, Healthcare Industry, Bristol Myers Squibb, TheStreetcom, Media, Computers

Wed Nov 04, 2009

BusinessWeek

J &J slashing workfor...

Johnson & Johnson plans to cut up to 7 percent of its workforce in order to generate cost savings needed to finance increasingly costly drug research and to weather future challenges, the diversified healthcare company said on Tuesday.

Comment?

Related Topix: Food, J and J Snack Foods, Biotech, Johnson and Johnson, Medicine, Healthcare Industry, New Brunswick, NJ

Sat Oct 31, 2009

Seeking Alpha

J&J's New Acquisition Strategy Makes Sense

Johnson & Johnson's CEO has given an interview to the Financial Times explaining his company's strategy with acquisitions.

Comment?

Related Topix: Food, J and J Snack Foods, Biotech, Johnson and Johnson, Medicine, Healthcare Industry, Crucell NV

Thu Oct 29, 2009

The Motley Fool

5-Star Stocks Poised to Pop: MEMC

Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS , the Fool's free investing community, silicon-wafer maker MEMC Electronic Materials has earned a coveted five-star ranking .

Comment?

Related Topix: Semiconductors, Memc Electronic Materials, Electronics, Financial Markets, Biotech

Wed Oct 28, 2009

GlobeNewswire

Trading Outlook for Elan Corp. Plc. Issued by InvestorSoup.com

InvestorSoup.com announces an investment report featuring Elan Corp. Plc. . The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Biogen Idec, Genzyme General, Telecom, Security, Lifeline Systems

Mon Oct 26, 2009

Motley Fool

4-Star Stocks Poised to Pop: Elan

Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS , the Fool's free investing community, Irish biotech Elan has earned a respected four-star ranking .

Comment?

Related Topix: Biotech, Financial Markets, Ireland, World News, Oakland, CA, Medicine, Multiple Sclerosis, Health

TheStreet.com

Biogen, Elan Fall on Brain Infection Fears

Shares of Biogen Idec fell Friday as European regulators investigate reports of 23 cases of Tysabri patients with a potentially fatal brain infection.

Comment?

Related Topix: Biotech, Biogen Idec, Business News

Sat Oct 24, 2009

The Irish Times

Elan shares slump over Tysabri drug review

SHARES IN Elan slumped yesterday after the European Medicinces Agency announced a review of the risks and benefits of its key multiple sclerosis drug Tysabri in the wake of 23 cases of a rare and potentially fatal brain disease since it came to market.

Comment?

Related Topix: Biotech, Medicine, Multiple Sclerosis, Health, Food and Drug Administration

Fri Oct 23, 2009

MarketWatch

Biogen, Elan fall; Dr. Reddy's rallies

Partners Biogen Idec and Elan Corp. led drug stocks lower early Friday as shares of the companies fell on news that European regulators were reviewing the safety of their multiple sclerosis drug Tysabri.

Comment?

Related Topix: Biotech, Financial Markets, Dr Reddys Laboratories

Wed Oct 21, 2009

MarketWatch

Earnings Watch: Updates, advisories and surprises

Earnings from continuing operations were 77 cents a share. Sales were $936 million compared to $1.12 billion a year ago.

Comment?

Related Topix: Media, Computers, FactSet Research Systems, IT Services, Altria Group, Tobacco, MarketWatch, Startups, Omnicom Group, Advertising, Knight Trading Group, Financial Services, Investment Services, Jersey City, NJ

Waunakee Jobs

Also on Topix